{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:02:41Z","timestamp":1790431361662,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004726","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IRCCS Foundation Policlinico San Matteo","award":["RC 2017-08004517"],"award-info":[{"award-number":["RC 2017-08004517"]}]},{"DOI":"10.13039\/501100004726","name":"Ministry of Health","doi-asserted-by":"publisher","award":["2013-0943"],"award-info":[{"award-number":["2013-0943"]}],"id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jconrel.2019.08.015","type":"journal-article","created":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T10:57:05Z","timestamp":1566039425000},"page":"198-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis"],"prefix":"10.1016","volume":"310","author":[{"given":"Veronica","family":"Codullo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Cova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3194-8027","authenticated-orcid":false,"given":"Vanessa","family":"Frangipane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Malatesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Calderan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Cagnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pacini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cavagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helios","family":"Recalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg H.W.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Giustra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-9575","authenticated-orcid":false,"given":"Davide","family":"Prosperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3428-5668","authenticated-orcid":false,"given":"Miriam","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10103","key":"10.1016\/j.jconrel.2019.08.015_bb0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet Lond Engl."},{"issue":"11","key":"10.1016\/j.jconrel.2019.08.015_bb0010","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jconrel.2019.08.015_bb0015","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2019.08.015_bb0020","article-title":"Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease","author":"Khanna","year":"2018","journal-title":"Rheumatol Oxf Engl."},{"issue":"2","key":"10.1016\/j.jconrel.2019.08.015_bb0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.39865","article-title":"Review: Frontiers of Antifibrotic therapy in systemic sclerosis","volume":"69","author":"Distler","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"issue":"3","key":"10.1016\/j.jconrel.2019.08.015_bb0030","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/BOR.0b013e3283524b9a","article-title":"Innovative antifibrotic therapies in systemic sclerosis","volume":"24","author":"Beyer","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"issue":"10","key":"10.1016\/j.jconrel.2019.08.015_bb0035","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/rheumatology\/keu216","article-title":"Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study","volume":"53","author":"Pope","year":"2014","journal-title":"Rheumatol Oxf Engl."},{"issue":"4","key":"10.1016\/j.jconrel.2019.08.015_bb0040","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2019.08.015_bb0045","article-title":"Imatinib mesylate (Gleevec\u00ae) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial","volume":"32","author":"Gordon","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"issue":"11","key":"10.1016\/j.jconrel.2019.08.015_bb0050","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/art.30548","article-title":"Open-label pilot trial of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis- associated active interstitial lung disease (SSc-ILD)","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jconrel.2019.08.015_bb0055","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2019.08.015_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/nnm.13.208","article-title":"Antibody-engineered nanoparticles selectively inhibit mesenchymal cells isolated from patients with chronic lung allograft dysfunction","volume":"10","author":"Cova","year":"2015","journal-title":"Nanomed."},{"issue":"4","key":"10.1016\/j.jconrel.2019.08.015_bb0065","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/17435390.2017.1317862","article-title":"Bioengineered gold nanoparticles targeted to mesenchymal cells from patients with bronchiolitis obliterans syndrome does not rise the inflammatory response and can be safely inhaled by rodents","volume":"11","author":"Cova","year":"2017","journal-title":"Nanotoxicology."},{"issue":"7","key":"10.1016\/j.jconrel.2019.08.015_bb0070","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1039\/C39940000801","article-title":"Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid\u2013liquid system","volume":"0","author":"Brust","year":"1994","journal-title":"J. Chem. Soc. Chem. Commun."},{"issue":"4","key":"10.1016\/j.jconrel.2019.08.015_bb0075","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1021\/nl035172j","article-title":"Hydrophobic nanocrystals coated with an amphiphilic polymer shell: a general route to water soluble nanocrystals","volume":"4","author":"Pellegrino","year":"2004","journal-title":"Nano Lett."},{"issue":"11","key":"10.1016\/j.jconrel.2019.08.015_bb0080","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"Van den Hoogen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.jconrel.2019.08.015_bb0085","first-page":"1681","article-title":"Effect of a neutrophil elastase inhibitor on ventilator-induced lung injury in rats","volume":"6","author":"Do-Hyung","year":"2014","journal-title":"J Thorac Dis."},{"key":"10.1016\/j.jconrel.2019.08.015_bb0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jcp.41.4.467","article-title":"Simple method of estimating severity of pulmonary fibrosis on a numerical scale","volume":"41","author":"Ashcroft","year":"1988","journal-title":"J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.jconrel.2019.08.015_bb0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/01902148.2014.939312","article-title":"Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib","volume":"41","author":"Chilakapati","year":"2015","journal-title":"Exp. Lung Res."},{"issue":"11","key":"10.1016\/j.jconrel.2019.08.015_bb0100","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200404-531OC","article-title":"Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice","volume":"171","author":"Aono","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.jconrel.2019.08.015_bb0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1164\/rccm.201010-1719OC","article-title":"Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis","volume":"184","author":"Gibbons","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.jconrel.2019.08.015_bb0110","first-page":"111","article-title":"BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis","volume":"21","author":"Meloni","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG."},{"issue":"602","key":"10.1016\/j.jconrel.2019.08.015_bb0115","article-title":"Macrophages during the fibrotic process: M2 as friend and foe","volume":"6","author":"Braga","year":"2015","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2019.08.015_bb0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.molmed.2016.02.004","article-title":"Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease?","volume":"22","author":"Byrne","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2019.08.015_bb0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2015.11.003","article-title":"Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis","volume":"221","author":"Lin","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.08.015_bb0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2018.09.004","article-title":"Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis","volume":"288","author":"Kurniawan","year":"2018","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2019.08.015_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharep.2015.05.024","article-title":"Imatinib reduces cholesterol uptake and matrix metalloproteinase activity in human THP-1 macrophages","volume":"68","author":"Gacic","year":"2016","journal-title":"Pharmacol Rep PR."},{"key":"10.1016\/j.jconrel.2019.08.015_bb0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.phrs.2018.05.002","article-title":"Imatinib prevents lung cancer metastasis by inhibiting M2-like polarization of macrophages","volume":"133","author":"Yao","year":"2018","journal-title":"Pharmacol. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591930495X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591930495X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T23:59:40Z","timestamp":1569542380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591930495X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":28,"alternative-id":["S016836591930495X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.08.015","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}